Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants
- PMID: 29713485
- PMCID: PMC5922572
- DOI: 10.1136/openhrt-2018-000788
Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants
Abstract
Randomised controlled trials (RCTs) provide the reference standard for comparing the efficacy of one therapy or intervention with another. However, RCTs have restrictive inclusion and exclusion criteria; thus, they are not fully representative of an unselected real-world population. Real-world evidence (RWE) studies encompass a wide range of research methodologies and data sources and can be broadly categorised as non-interventional studies, patient registries, claims database studies, patient surveys and electronic health record studies. If appropriately designed, RWE studies include a patient population that is far more representative of unselected patient populations than those of RCTs, but they do not provide a robust basis for comparing treatment strategies. RWE studies can have very large sample sizes, can provide information on treatments in patient groups that are usually excluded from RCTs, are generally less expensive and quicker than RCTs, and can assess a broad range of outcomes. Limitations of RWE studies can include low internal validity, lack of quality control surrounding data collection and susceptibility to multiple sources of bias for comparing outcomes. RWE studies can complement the findings from RCTs by providing valuable information on treatment practices and patient characteristics among unselected patients. This information is necessary to guide treatment decisions and for reimbursement and payment decisions. RWE studies have been extensively applied in the postmarketing approval assessment of non-vitamin K antagonist oral anticoagulants since 2010. However, the benefits, costs, limitations and methodological challenges associated with the different types of RWE must be considered carefully when interpreting the findings.
Keywords: anticoagulant; limitations; real-world evidence.
Conflict of interest statement
Competing interests: AJC has received research grants and speaker’s honoraria, and participated in scientific advisory boards for Bayer, Daiichi Sankyo, Bristol-Myers Squibb-Pfizer and Boehringer Ingelheim. KAAF has received grants and honoraria from Bayer and Janssen.
Figures
Similar articles
-
Translational hurdles with cannabis medicines.Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1325-1330. doi: 10.1002/pds.4999. Epub 2020 Apr 12. Pharmacoepidemiol Drug Saf. 2020. PMID: 32281186 Review.
-
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism.BMC Med. 2023 Sep 29;21(1):375. doi: 10.1186/s12916-023-03069-1. BMC Med. 2023. PMID: 37775786 Free PMC article.
-
Payer perceptions of the use of real-world evidence in oncology-based decision making.J Manag Care Spec Pharm. 2021 Aug;27(8):1096-1105. doi: 10.18553/jmcp.2021.27.8.1096. J Manag Care Spec Pharm. 2021. PMID: 34337998 Free PMC article.
-
Use of real-world evidence in meta-analyses and cost-effectiveness models.J Med Econ. 2020 Oct;23(10):1053-1060. doi: 10.1080/13696998.2020.1792917. Epub 2020 Jul 28. J Med Econ. 2020. PMID: 32657189
-
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.Clin Ther. 2019 Feb;41(2):336-349. doi: 10.1016/j.clinthera.2018.12.013. Epub 2019 Jan 30. Clin Ther. 2019. PMID: 30709609 Review.
Cited by
-
Diuretics versus others for long-term clinical outcomes as first-line antihypertensive medications: analysis of national real-world database.Hypertens Res. 2022 May;45(5):758-768. doi: 10.1038/s41440-022-00890-8. Epub 2022 Mar 25. Hypertens Res. 2022. PMID: 35338336
-
Use of Telehealth Services for Prenatal Care in Mississippi: Comparison of Pre-COVID-19 Pandemic and Pandemic Obstetric Management.Int J Clin Pract. 2022 Jan 31;2022:3535700. doi: 10.1155/2022/3535700. eCollection 2022. Int J Clin Pract. 2022. PMID: 35685499 Free PMC article.
-
Real World Studies of Psoriasis and Mental Illness in Newfoundland and Labrador.J Cutan Med Surg. 2022 Sep-Oct;26(5):494-501. doi: 10.1177/12034754221117736. Epub 2022 Aug 7. J Cutan Med Surg. 2022. PMID: 35938546 Free PMC article.
-
Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries.Clin Cardiol. 2023 Nov;46(11):1398-1407. doi: 10.1002/clc.24109. Epub 2023 Aug 18. Clin Cardiol. 2023. PMID: 37596725 Free PMC article.
-
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.J Manag Care Spec Pharm. 2023 Sep;29(9):985-998. doi: 10.18553/jmcp.2023.29.9.985. J Manag Care Spec Pharm. 2023. PMID: 37610110 Free PMC article.
References
-
- Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423–34. - PubMed
-
- Association of the British Pharmaceutical Industry (ABPI). The vision for real world data – harnessing the opportunities in the UK. Demonstrating value with real world data. London, UK: Association of the British Pharmaceutical Industry, 2011.
-
- Cohen AT, Goto S, Schreiber K, et al. . Why do we need observational studies of everyday patients in the real-life setting?: Table 1. European Heart Journal Supplements 2015;17:D2–D8. 10.1093/eurheartj/suv035 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical